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Interferons (IFNs) are well described to be rapidly induced upon pathogen-associated 
pattern recognition. After binding to their respective IFN receptors and activation of the 
cellular JAK/signal transducer and activator of transcription signaling cascade, they 
stimulate the transcription of a plethora of IFN-stimulated genes (ISGs) in infected as well 
as bystander cells such as the non-infected epithelium and cells of the immune system. 
ISGs may directly act on the invading pathogen or can either positively or negatively 
regulate the innate and adaptive immune response. However, IFNs and ISGs do not only 
play a key role in the limitation of pathogen spread but have also been recently found 
to provoke an unbalanced, overshooting inflammatory response causing tissue injury 
and hampering repair processes. A prominent regulator of disease outcome, especially 
in—but not limited to—respiratory viral infection, is the IFN-dependent mediator TRAIL 
(TNF-related apoptosis-inducing ligand) produced by several cell types including immune 
cells such as macrophages or T cells. First described as an apoptosis-inducing agent 
in transformed cells, it is now also well established to rapidly evoke cellular stress path-
ways in epithelial cells, finally leading to caspase-dependent or -independent cell death. 
Hereby, pathogen spread is limited; however in some cases, also the surrounding tissue 
is severely harmed, thus augmenting disease severity. Interestingly, the lack of a strictly 
controlled and well balanced IFN/TRAIL signaling response has not only been implicated 
in viral infection but might furthermore be an important determinant of disease progres-
sion in bacterial superinfections and in chronic respiratory illness. Conclusively, the IFN/
TRAIL signaling axis is subjected to a complex modulation and might be exploited for the 
evaluation of new therapeutic concepts aiming at attenuation of tissue injury.
Keywords: interferon, interferon-stimulated genes, tumor necrosis factor-related apoptosis-inducing ligand, 
acute lung injury, innate immunity, influenza, respiratory syncytial virus, coronavirus
TABLe 1 | Major effects of the interferon (iFN)/tumor necrosis factor-related apoptosis-inducing ligand (TRAiL) signaling axis on host cells in respiratory 
viral infection.
effect virus Reference
IFN Virus control by antiviral interferon-stimulated genes induction Influenza A virus (IAV) (58–60)
Coronaviruses (CoV) (63, 64)
Respiratory syncytial virus (RSV) (62)
e.g., via
Interferon-induced transmembrane proteins IAV, West Nile virus (50, 51)
Myxovirus resistance protein A Vesicular stomatitis virus, IAV (52–54)
ISG20 IAV (57)
Restriction of immunopathology IAV (88)
CoV (63, 64)
RSV (62)
Enhanced inflammatory response contributing to tissue damage, morbidity, and mortality CoV (76)
IAV (74, 95, 98)
RSV (67)
Sendai virus (73)
Cell death induction, e.g., Bcl-2-associated X protein, caspase-8, Fas-associated protein 
with death domain, Fas ligand, and TNF-related apoptosis-inducing ligand (TRAIL)
dsRNA, polyI:C (4, 110)
IAV (4, 5, 10, 115)
Sendai virus (110)
TRAIL Virus control by apoptosis induction in infected cells IAV (6, 170, 171)
Tissue injury by apoptosis of both infected and non-infected alveolar epithelial cells, lung 
macrophages
IAV (5, 7, 10)
RSV (137)
Necrosis of fibroblasts, dendritic cells, and epithelial cells IAV (146, 147, 168)
Increased cellular infiltration CoV (175)
Decreased expression of Na,K-ATPase, impaired epithelial fluid reabsorption IAV (11)
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iNTRODUCTiON
In 1957, Isaacs and Lindenmann (1) first recognized the potential 
of a soluble and probably cell-derived factor to combat influenza 
virus infection and named this factor interferon [(IFN) from 
latin interferre, to interfere]. Since then, three subgroups of IFNs 
have been defined, primarily by their differential receptor usage. 
While the groups of type I IFN and type III IFN comprise largely 
agents directly limiting pathogen spread by improving cellular 
counter measurements, IFN-γ, the sole type II IFN, has been 
mainly implicated in the modulation of innate and also adaptive 
immune responses (2, 3). Accordingly, type I and III IFNs are key 
signaling molecules in viral control, and lack of both signaling 
pathways results in increased viral loads and disease severity. Still, 
there is accumulating evidence that not only lack of an antiviral 
response but that also an unbalanced overshooting activation 
of IFNs contributes to an exaggerated inflammatory reaction, 
tissue injury, reduced proliferative capacity, and thus enhanced 
disease severity (Table  1). Especially in viral infections, this 
effect has not only been tracked down to IFN signaling in general 
but specifically to the exaggerated production of key effector 
IFN-stimulated genes (ISGs) (4). A prominent example is the 
TNF-related apoptosis-inducing ligand (TRAIL) that displays an 
ambivalent role in viral infection (5–7) (Table 1). Whereas first 
identified as factor produced by immune cells in non-respiratory 
infection (8, 9), TRAIL is now especially well studied in influenza 
A virus (IAV) infection, where it is released in high amounts 
from bone marrow-derived macrophages upon pathogen-
associated molecular patterns (PAMPs) recognition and type I 
IFN production (10). Macrophage-released soluble TRAIL, but 
also membrane-bound cell-associated TRAIL, acts via distinct 
receptors on infected but also on non-infected, neighboring cells. 
In viral infection, its preliminary role is to drive infected cells 
into apoptosis to limit virus spread. However, studies performed 
within the last decade demonstrate that TRAIL’s antiviral activity 
seems to be outweighed by the functional and structural damage 
it induces not only in infected but also in bystander cells such as 
uninfected cells of the alveolar epithelium (10, 11). This process 
is not only relevant in promoting viral disease progression but 
has further implications in bacterial superinfection and probably 
also in chronic diseases. The recognition of the ambivalent role 
of IFN-driven signaling in vivo is a first important step to better 
understand disease progression and to envision novel treatment 
options for primary viral respiratory infection targeting distinct 
host-derived signaling mediators such as TRAIL.
FROM PATTeRN ReCOGNiTiON TO 
iSGs—BASiC PRiNCiPLeS OF iFN 
SiGNALiNG
iFN induction upon virus Recognition
It is a commonly accepted concept that—as Janeway (12) 
already proposed in 1989—immune activation toward invading 
FiGURe 1 | PRRs and their downstream signaling pathways in virus-induced iFN induction. In viral infection, type I IFNs are induced by TLR, RLR, CLR, 
and cytosolic nucleic acid sensors. Cell membrane-located TLRs ligate to viral envelope proteins (e.g., TLR2/herpes simplex virus), upon which they recruit MyD88. 
MyD88 interacts with IRAK kinase (IRAK-1, -2, or -4) that either directly activate IRF1 or interact with TRAF6, which induces IRF7 or assembles with TAK1. TAK1 
forms a complex with TAB-1/-2 and -3 and subsequently either activates the MAPK kinases p38 and JNK, leading to AP-1 phosphorylation and nuclear 
translocation, or induces ubiquitination of NEMO followed by IκB degradation and NFκB activation. Endosomal TLRs recognizing viral nucleic acid and signal via the 
adaptor protein MyD88 (for TLR7/8/9) or interact with TRIF (for TLR3) followed by TRAF3, TANK, and TBK1 activation. TBK1 and IKKε then phosphorylate and 
activate IRF3 and IRF7. Additionally, TRIF can interact with TRAF6 to initiate TAK1 signaling. Both RLRs, RIG-I and MDA-5, recognize nucleic acid contents in the 
cytoplasm and stimulate the mitochondrial anchored IPS-1 for dimerization followed by TRADD recruitment that acts via TRAF3 on IRF3 and IRF7. Additionally, 
IPS-1 can interact with FADD and RIP1 to activate NFκB via IKK activated by caspase-8 and -10. Also PKR signaling results in NFκB activation and nuclear 
translocation. The dsDNA sensor cGAS produces cGAMP that activates ER-located STING that via TBK1 induces IRF3 translocation and type I IFN production. 
CLRs play a minor role in viral recognition; however, DC-SIGN activates the small GTPase Ras and Raf protein kinase, followed by NFκB activation. Type III IFN are 
induced by TLR3, TLR9, and via RIG-I and peroxisomal-resident IPS-1. Especially IRF1, but also NFκB, IRF3, and IRF7 are implicated in IFN-λ production, with the 
latter being stabilized by Med23. Abbreviations: TLR, toll-like receptor; RIG-I, retinoic acid-inducible gene; RLR, RIG-I-like receptors; CLR, C-type lectin receptors; 
PRR, pattern recognition receptor; MITO, mitochondrium; ER, endoplasmatic reticulum; IFN, interferon; MyD88, myeloid differentiation factor 88; IRAK, interleukin-1 
receptor-associated kinase; IRF, IFN regulatory factor; TRIF, TIR-domain-containing adaptor protein-inducing IFN-β; TNF, tumor necrosis factor; TRAF, TNF 
receptor-associated factor; TAK, transforming growth factor β-activated kinase 1; TAB, TAK1-binding protein; NEMO, essential modulator; IKK, inhibitor-κB kinase; 
JNK, c-Jun N-terminal kinase; AP-1, activator protein 1; TANK, TRAF family member-associated NF-κB activator; TBK, TANK-binding kinase; MDA-5, melanoma 
differentiation antigen 5; TRADD, TNF receptor type 1-associated death protein; IPS-1, IFN-β promoter stimulation 1; FADD, Fas-associated protein with death 
domain; RIP1, receptor-interacting serine/threonine-protein kinase 1; PKR, protein kinase R; cGAS, cyclic GMP–AMP synthase; cGAMP, cyclic guanosine 
monophosphate–adenosine monophosphate; STING, stimulator of IFN genes; DC-SIGN, dendritic cell-specific ICAM3-grabbing non-integrin; AIM-2, absent in 
melanoma 2; Med23, mediator complex subunit 23; TRAF3, TNF receptor-associated factor 3.
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pathogens is mounted upon recognition of PAMPs. PAMPs are 
evolutionary conserved biomolecules such as proteins, lipids, 
nitrogen bases, sugars, and complexed biomolecules such as 
lipoglycans that are essential to the survival of a given pathogen 
(13). PAMPs are recognized by distinct pattern recognition 
receptors (PRRs) that are germ-line encoded and—similar to 
PAMPs—usually show a high evolutionary conservation. The 
first recognized and probably most intensely studied family of 
PRRs are the toll-like receptors [TLRs; reviewed in Mogensen 
(14); Leifer and Medvedev (15)]. In viral infection, both host cell 
membrane-localized TLRs (TLR2, TLR4, detecting viral enve-
lope proteins) and endosomal TLRs (TLR3, TLR7, TLR8, and 
TLR9, nucleic acid sensors) initiate signal transduction cascades 
leading to IFN production (Figure 1). TLR activation results in 
either myeloid differentiation factor 88 (MyD88) or TIR-domain-
containing adaptor protein-inducing IFN-β (TRIF) recruitment 
that both trigger various downstream signaling events, eventually 
leading to IFN regulatory factor (IRF)3, IRF7, and NFκB nuclear 
translocation as well as MAP kinase and activator protein 1 (AP-1) 
activation (16, 17).
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Similar to endosomal TLRs, the cytosolic retinoic acid-
inducible gene (RIG)-I-like receptors (RLRs) are specialized 
to recognize viral nucleic acid contents and are central PRRs 
relevant to mount an antiviral response, providing resistance 
to most RNA (e.g., orthomyxoviruses) and some DNA (e.g., 
reoviruses) viruses [reviewed in Ref. (18, 19)]. Both melanoma 
differentiation-associated gene 5 (MDA-5) and RIG-I recognize 
dsRNA, 5′-triphosphate RNA, or the synthetic analog to dsRNA, 
polyI:C (20, 21). Both drive the dimerization of the mitochondria-
associated adaptor protein IFN-β promoter stimulation 1 (IPS-1) 
(also named MAVS, VISA, CARDIF). A subsequently activated 
cascade including TRADD (TNF receptor type 1-associated 
death domain protein), TRAF3 (TNF receptor-associated factor 
3), and TANK (TRAF family member-associated NF-κB activa-
tor) induces the phosphorylation of IRF3 and IRF7, resulting 
in type I IFN production (22). The third RLR, LGP2, so far has 
primarily been implicated to regulate RIG-I or MDA-5 as a cofac-
tor; however, a recent study by Stone et  al. (23) demonstrated 
a novel, non-redundant, and independent role of LGP2 in West 
Nile virus infection. Another class of PRR, the nucleotide oli-
gomerization domain (NOD)-like receptors (NLRs), has mainly 
been implicated in bacterial recognition (24), still several NLRs 
are activated as well upon virus infection. Especially, NLRP3 is 
known to recognize RNA of different viruses including hepatitis 
C virus, measles virus, influenza, and vesicular stomatitis virus 
(VSV) (25–28), resulting in inflammasome formation and 
caspase-1-dependent activation of IL-1β and IL-18 (29–31). In 
addition, virus infections are sensed also by a structurally diverse 
group of viral RNA and DNA sensors residing in the cytoplasm. 
These include the cyclic GMP–AMP synthase that synthesizes the 
second messenger cGAMP. cGAMP in turn activates stimulator 
of IFN genes (STING), TANK-binding kinase 1, and IRF3, trig-
gering IFN production (32–34). Moreover, STING itself acts 
as a PRR and has been implicated in DNA virus recognition 
including HSV, adenovirus, vaccinia virus, and papilloma virus 
and in sensing of retroviral RNA–DNA hybrids (35) and RNA 
viruses after being activated by RIG-I (36, 37). Another cytosolic 
nucleic acid sensor, PKR, is well known for its phosphorylation 
of eukaryotic initiation factor 2 α (eIF2α) in response to viral 
dsRNA. Phosphorylation of eIF2α results in its deactivation, 
host translational shut-off, and the limitation of viral replication. 
Of note, the PKR–eIF2α-driven inhibition of protein synthesis 
can contribute to an IPS-1-dependent IFN-β induction (38). 
Furthermore, PKR has been implicated in efficient type I IFN 
activation by TLR3 in response to dsRNA (39) and can medi-
ate—at least partially—activities of IRF1 (40).
In addition to type I IFNs, also type III IFNs exert antiviral 
activity and are widely expressed after viral recognition, being 
produced by most cell types including epithelial, endothe-
lial, fibroblast, and polymorphonuclear cells [reviewed in 
Ref. (41, 42)]. Like type I IFNs, type III IFNs are induced in viral 
infection by the PRR RIG-I as well as TLR3 and TLR9 and rely 
on the activation of the same transcriptional activators, includ-
ing IRF3, IRF7, and NFκB. These observations initially led to 
the conclusion that type I and type III IFN comprised two com-
pletely redundant systems to induce ISGs in response to PAMP 
recognition. However, more recent data suggest distinct selection 
mechanisms for either type I or type III IFN expression. As such, 
IPS-1 specifically induces IFN-λ, but not type I IFN, when located 
at the peroxisomal membrane instead of the mitochondrial mem-
brane in response to RIG-I activation by reovirus, Sendai virus, or 
dengue virus challenge (43). Interestingly, type III IFN induction 
is largely independent toward AP-1 translocation, which facili-
tates an instantaneous induction of IFN-λ after viral recognition, 
highlighting it as an important immediate factor driving innate 
microbial defense mechanisms.
JAK/STAT-Dependent induction of iSGs
Release of IFNs upon pathogen recognition is a highly conserved 
mechanism—found from teleost fish to insects and mammals—to 
prepare the surrounding cells as well as the host defense against 
the invading threat (44, 45). Whereas often high-level IFN pro-
duction relies on specialized sentinel cells such as macrophages or 
dendritic cells (DCs), mostly all cells of the multicellular organ-
isms are able to respond to at least one type of IFN by expression 
of respective receptors. Receptor binding then induces a signal 
transduction cascade relying on the Janus kinase (JAK) and 
Signal Transducer and Activator of Transcription (STAT), which 
results in efficient transcription of a plethora of different ISGs in 
infected as well as bystander cells (46, 47). IFNs engage a classi-
cal canonical signal transduction cascade employing JAK/STAT 
molecules after binding to their respective receptors. Herein, type 
I IFNs ligate to their common heterodimeric receptor consisting 
of the IFN-α receptor (IFNAR)1 and IFNAR2 subunits, whereas 
type III IFNs act via a interleukin-10 receptor 2 (IL-10R2)/IFN-λ 
receptor 1 (IFNLR1) heterodimer that to date has been reported 
to be restricted in its expression to epithelial cells (48). In type I 
IFN signaling, IFNAR engagement leads to the activation of the 
receptor-associated protein tyrosine kinases JAK1 and tyrosine 
kinase 2 followed by the recruitment or repositioning of already 
associated but elsewise latent cytoplasmatic transcription factors 
STAT1 and STAT2. Consequently, STAT1/STAT2 are phos-
phorylated on conserved tyrosine residues, they disassemble, 
undergo conformational changes enabling their heterodimeriza-
tion as well as the exposure of a nuclear localization sequence. 
Subsequently, the STAT1/STAT2 heterodimer translocates into 
the nucleus where it interacts with the IRF9 to form the trimeric 
IFN-stimulated factor 3 (ISGF3). ISGF3 binds cognate DNA 
sequences, the IFN-stimulated response elements (ISRE), finally 
leading to ISG induction. Also type III IFN interaction with the 
IL-10R2/IFNLR1 receptor complex triggers STAT1/STAT2 heter-
odimerization, nuclear translocation, and ISGF3 assembly (49).
iFNs iN ACUTe ReSPiRATORY viRAL 
iNFeCTiON
Interferon signaling results in the induction of ISGs evoking 
different cellular responses against viral infection, both in 
infected as well as in non-infected cells, including direct antiviral, 
immune-modulatory, or cell death-inducing effects to enable an 
immediate and robust response to a pathogen challenge. Many 
ISGs directly interfere with viral replication on an intracel-
lular level. Well-studied examples of antiviral ISGs comprise 
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IFN-induced transmembrane proteins (IFITMs) effective in IAV, 
West Nile virus, and dengue virus infection (50, 51), the myxovi-
rus resistance protein A (MxA) that interferes with VSV mRNA 
production and binds the IAV nucleocapsid to prevent nuclear 
translocation of viral genetic material (52–54), the 2-5-oligoad-
enylate synthase (OAS), which activates RNAse L triggering viral 
RNA degradation, or the PRR PKR, which besides activating the 
IFN response has a major impact on viral protein translation by 
inhibiting the eIF2α (55). More recently identified ISGs include 
the plasminogen activator inhibitor 1 that blocks IAV infection 
by inhibiting glycoprotein cleavage executed by extracellular 
airway proteases (56) or the antiviral ISG20 that limits IAV viral 
replication via its exonuclease activity most likely by interfering 
with the viral NP (57).
Accordingly, IFN pretreatment usually results in the 
establishment of an antiviral state that limits viral replication 
and spread from the start of infection and thus favors milder 
disease outcomes. IFN-α pretreatment has been demonstrated to 
limit viral spreading of seasonal IAV strains and thus decrease 
morbidity and mortality in mice, guinea pigs as well as ferrets 
(58–60). As shown by a study by Tumpey et al. (61), this effect 
can be attributed to the early induction of antiviral ISGs including 
MxA. Importantly, type I IFN pretreatment also dampens early 
replication of highly pathogenic avian influenza in ferrets (58). 
Also in respiratory syncytial virus (RSV) infection, treatment 
with recombinant IFN-α results in significantly decreased lung 
viral titers, alveolar inflammatory cell accumulation, and clini-
cal disease in RSV-infected mice (62). In addition, respiratory 
infections caused by emerging coronaviruses (CoV) can be 
ameliorated by type I IFN pretreatment strategies. In an in vivo 
macaque model (Macaca fascicularis) of severe acute respiratory 
syndrome (SARS)-CoV infection, it could be demonstrated that 
pretreatment with pegylated IFN-α significantly diminished CoV 
replication and excretion and resulted in reduced pulmonary 
damage (63). Macaques also serve as a preclinical model for 
Middle East respiratory syndrome (MERS)-CoV, and similar to 
SARS-CoV, IFN-α in combination therapy with ribavirin reduces 
viral replication and severe histopathological changes (64).
In line, genetic alteration leading to an enhanced type I IFN 
signaling has been demonstrated to limit IAV-induced disease 
outcomes, as a recent study by Xing et  al. (65) reported that 
deletion of TRIM29, a negative regulator of NEMO, which leads 
to NFκB induction and therefore enhanced type I IFN produc-
tion, is protective in vivo in IAV-infected mice. Conversely, the 
genetic depletion of IFN signaling in IFN receptor-deficient mice 
can result in a lack of viral control, resulting in enhanced viral 
titers in different viral infections including RSV or IAV (66, 67). 
Still, it must be noted that this effect is often mild in IFNAR- or 
IFNLR-deficient animals, which is probably related to a certain 
redundancy between type I and type III IFN signaling in limit-
ing viral spreading in epithelial cells (68). In contrast, IFNAR/
IFNLR-double knockout or STAT1 knockout animals that are 
deficient in both type I and type III IFN signal transduction 
succumb more readily to infection due to excessive viral replica-
tion (69–71). Vice versa, mutations in key ISGs such as IFITM3 
are associated with increased IAV disease severity in mice and 
humans (72).
However, IFN pretreatment and genetic loss-of-function 
approaches generally are not relevant to human respiratory 
virus-induced hospitalizations, where patients already present 
with ongoing respiratory infection and inflammation, and 
preclinical studies underline that type I IFN signaling in an 
already inflamed organ is rather detrimental and enhances tis-
sue injury, and lack of type I IFN in vivo may even ameliorate 
disease outcome. Accordingly, in cases where the antiviral 
defense was not compromised (e.g., in animals with efficient 
type III IFN signaling) IFNAR-deficient mice infected with 
Sendai virus or IAV were reported to be more resistant to 
infection-induced morbidity and mortality (73, 74). Similarly, 
in Sendai virus in vivo infection, Wetzel et al. (75) showed that 
increased IFN-β levels in the lung homogenate correlates to 
increased morbidity and mortality, and also for SARS-CoV, a 
recent study demonstrates that high type I IFN induction in 
an already ongoing viral infection contributes to mortality in 
SARS-CoV-infected mice (76). Also for IAV infection, type I 
IFN application after infection has been proven to drive disease 
severity (74). Of note, the detrimental effects of type I IFNs 
were especially pronounced in mice lacking central antiviral 
factors, namely the IFIT protein in Sendai virus infection and 
MxA in IAV. Interestingly, Beilharz et al. (77) demonstrated that 
application of low doses of IFN-α reduces viral load, which to 
a certain degree led to attenuated disease progression, whereas 
high dose application of type I IFN contributed to morbidity 
(77). In line, high expression levels of ISGs have been shown to 
correlate to worse outcomes in ARDS patients (78). This obser-
vation corresponds to reports stating that the IFN threshold 
needed to induce antiviral ISGs—showing a beneficial effect 
in acute respiratory viral infection—is by at least 10-fold lower 
than the IFN dose necessary to trigger ISGs that show immu-
nomodulatory, death-inducing, or anti-proliferative effects and 
thus can contribute to disease progression (79–82). Altogether, 
these data demonstrate that IFNs may significantly contribute 
to unbalanced inflammation and tissue injury during respira-
tory viral infection depending on expression levels and duration 
of IFN-related signaling events.
To date, the underlying mechanisms leading to the IFN-
dependent enhanced disease progression are not fully understood 
but often result from a dysregulated IFN signaling response. One 
mode of action of IFN and IFN-stimulated ISGs is to stimulate 
negative feedback loops on IFN signaling. For example, suppres-
sion of JAK1 or STAT1 via specific phosphatases, expression 
of suppressor of cytokine signaling (SOCS)1 and SOCS3, or 
ubiquitination and endocytosis of the IFN receptors (83–86) 
desensitize cells to IFN signaling and allow recovery and the 
return to homeostasis after microbial challenge. As demonstrated 
by Bhattacharya et al. (87), the lack of IFNAR downregulation 
and thus the failure to initiate IFN-desensitization contributes 
to increased inflammatory signaling, extensive lung injury and, 
importantly, also impaired tissue regeneration (87). Moreover, 
IFNs are immunomodulatory and shape the specific responses of 
cells of the immune system, which has been implied to influence 
disease progression both positively and negatively. In a recent 
study, type I IFNs have been associated in the regulation of innate 
lymphoid immune cells (ILC)2 in IAV infection, where they—in 
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concert with IFN-γ and IL-27—promote an ILC2-dependent 
restriction of immunopathology (88). Moreover, type I IFNs 
play an important role in stimulating the immune response 
driven by DCs; they stimulate the expression of MHC molecules 
as well as the co-stimulatory ligands CD80 and CD86 and thus 
activate T  cell responses (89, 90). Additionally, ligand-driven 
activation of IFNAR enhances the proliferation of CD8 positive 
T cells, especially early in infection. However, late in infection, 
type I IFNs were also implied in decreasing T  cell expansion 
upon SARS-CoV and arenavirus infection (76, 91), which might 
potentially be related to the above described desensitization 
upon prolonged IFN signaling and might be detrimental if initi-
ated too early in infection. In line, Pinto et al. (92) reported an 
impairment of T cell responses upon type IFN induction in West 
Nile virus infection. In B cells, the lack of IFNAR has been dem-
onstrated to result in enhanced release of neutralizing antibodies 
in IAV infection (93) implying a repressive role for type I IFN 
in B cell antibody production. However, immunization studies 
by Le Bon et al. (94) reported the necessity of IFNAR on B cells 
for efficient IgM and IgG production, underlining the need for 
further studies to understand the detailed effects of IFN-dosage 
and timing adaptive immunity activity upon respiratory viral 
infection.
Type I IFNs additionally induce the production of high levels 
of pro-inflammatory cytokines that have been closely linked 
to worsened outcomes of acute respiratory viral infection. 
Especially in IAV, disease severity and disease progression are 
linked with an overshooting, IFN-driven inflammatory response, 
in which further exogenous supplementation with type I IFN in 
fact correlates with increased morbidity and mortality (74, 95). 
In non-human primates, IAV infection with a highly pathogenic 
H5N1 isolate evokes a strong induction of type I IFN, result-
ing in severe lung injury by a necrotizing bronchiolitis and 
alveolotis (96). IFN levels in turn have been demonstrated to 
cause elevated pro-inflammatory cytokine levels after in  vivo 
IAV infection and additionally, in human alveolar macrophages, 
the release of pro-inflammatory cytokines (e.g., MCP-1) are 
preceded by a robust type I IFN response (97). Importantly, 
also in human infection with H5N1, levels of pro-inflammatory 
cytokines are strongly elevated in bronchoalveolar lavage fluid, 
and cytokine levels have been associated with organ damage and 
worsened disease outcomes (98, 99). Still, it should be noted that 
due to strain differences in virus-elicited PRR activation and, 
importantly, IFN antagonism by the IAV non-structural (NS)1 
protein, IFN levels and disease severity do not always directly 
correlate; actually, the extent to which NS1 can suppress the 
IFN response relates to prolonged viremia and thus can also be 
a determinant of virus pathogenicity both in human bronchial 
epithelial cells and in an in vivo model of IAV infection (100, 
101). Alongside IAV, also in RSV infection the induction of high 
levels of pro-inflammatory cytokines has been directly related to 
type IFN, as RSV-infected but IFNAR-deficient mice presented 
with significantly diminished pro-inflammatory cytokine 
release, which translated into an attenuated disease course (67). 
Also in SARS-CoV, the late phase type I IFN induction relates 
to accumulation of inflammatory macrophage populations and 
elevated lung cytokine levels (76).
TRAiL iN ACUTe ReSPiRATORY viRAL 
iNFeCTiON—LiMiTATiON OF PATHOGeN 
SPReADiNG veRSUS iNDUCTiON OF 
TiSSUe iNJURY
Cell Death Pathways in iFN Signaling
In addition to antiviral, immunomodulatory, and pro-inflamma-
tory ISGs, IFN signaling results in the transcription and transla-
tion of cell death-inducing ISGs. In the context of viral infection, 
these factors provide a mode to block viral spreading and reinfec-
tion by killing those infected cells, in which the internal activation 
of antiviral ISGs is not sufficient to restrict viral replication. Thus, 
the infected cell is sacrificed to prevent the release of infectious 
progeny virions to limit viral spreading. However, especially 
in the lung, the disruption of the alveolar epithelial barrier by 
cell death of infected cells, but importantly also non-infected 
bystander cells induced by factors such as TRAIL, significantly 
contributes to worsened disease outcomes.
Controlled cell death or apoptosis can be induced by intrinsic 
and extrinsic signals. The intrinsic apoptosis pathway is initiated 
by diverse intracellular stimuli that influence the expression and 
activation of B cell lymphoma (Bcl)-2 family proteins that govern 
the permeabilization status of the outer mitochondrial membrane. 
Once cytochrome c is released from the mitochondria, it binds to 
the intracellular adaptor protein, apoptotic peptidase activating 
factor 1, forming the so-called apoptosome that in turn recruits 
pro-caspase-9 (102). Caspases (cysteine-aspartic proteases) exert 
their action by cleaving other proteins and substrates. Herein, 
initiator caspases such as caspase-8 and caspase-9 target other 
downstream caspases, whereas effector caspases, including 
caspase-3, -6, and -7, directly cause apoptosis by cleaving and 
thus inactivating or disassembling a vast array of cellular integral 
proteins and complexes (103). The extrinsic apoptosis pathway 
relies on an extracellular signal exerted by ligands of the tumor 
necrosis factor (TNF) receptor (TNFR) superfamily, including 
TRAIL, TNF-α, and Fas ligand (FasL) (104). Their ligation to 
their respective cell surface-expressed death receptors (DR) leads 
via the signal transmission by Fas-associated protein with death 
domain (FADD) to the activation of the initiator caspases-8 or 
-10, finally stimulating effector caspases including caspase-3 
(105).
To date, several type I and type III IFN-induced, proapoptotic 
factors have been identified (106). Both caspase-4 and caspase-8 
have been shown to be upregulated upon type I IFN signaling 
(4, 107); caspase-8 enhances the FADD-driven extrinsic apoptosis 
pathway, whereas the less-studied caspase-4 may promote pro-IL-
1β cleavage and inflammasome-driven cell death (pyroptosis) in 
macrophages (108, 109). Chattopadhyay et al. (110) demonstrated 
that Sendai virus infection and polyI:C treatment resulted in Bcl-
2-associated X protein (Bax) activation and apoptosis induction 
via one of the key transcription factors of IFN genes, IRF3. In 
addition IRF5 was reported to enhance TRAIL-dependent extrin-
sic apoptosis by nuclear translocation resulting in the translation 
of to date undefined factors that increase cell death upstream of 
caspase-8 activation (111). Furthermore, both RLRs, RIG-I and 
MDA-5, trigger the proteins Puma and Noxa that induce Bcl and 
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thus activate the intrinsic mitochondrial apoptotic cascade (112). 
Also, PKR influences a cell’s susceptibility to apoptotic signals, as 
it was demonstrated to sensitize to the FADD/caspase-8 apoptosis 
pathway upon type I IFN signaling after challenge with IAV or 
dsRNA (4) and the OAS-RNAseL system has been suggested to 
contribute to IFN-α-related cell death induction, but the exact 
mechanisms remain to be elucidated (113). Finally, also two clas-
sical initiators of the extrinsic apoptosis cascade are induced as 
ISGs. Both FasL and its receptor Fas are upregulated on mRNA 
levels by IFN-α (114), and FasL was reported to be induced by 
type I IFN in IAV infection in the murine lung in vivo (115). Also, 
the proapoptotic factor TRAIL (or TNFSF10, Apo2L) is induced 
by IFN-mediated and ISGF3-executed transcriptional activation, 
as has been shown by Sato et al. (116), who revealed the presence 
of the ISRE sequence within the TRAIL promoter region (116). In 
IAV infection, TRAIL is released in high amounts from infected 
alveolar macrophages depending on a PKR- and IFN-β-driven 
autocrine signaling loop. Binding of IFN-β to macrophage-
expressed IFNAR activates a JAK/STAT-dependent release of 
TRAIL, which then acts through its receptor DR5 on the alveolar 
epithelial cells (5, 10).
However, certain prerequisites may decrease the ability of a 
cell to undergo apoptosis, including a shortage in pro-caspase-8 
availability, expression of cellular FADD-like IL-1β-converting 
enzyme-inhibitory proteins (c-FLIPs) that block FADD-driven 
caspase activation, inactivation, or degradation of FADD itself, 
or expression of CYLD, which acts as a receptor-interacting 
serine/threonine-protein (RIP)1 kinase de-ubiquitinase and thus 
stabilizes RIP1. However, in these cases IFN signaling can still 
promote a caspase-independent, programmed inflammatory 
cell death by activating the necroptosis pathway (117, 118). 
Necroptosis is induced by a complex formation by RIP1 and RIP3 
kinases that activate both poly-ADP-ribose (PAR) polymerase 1 
(PARP-1) and/or mixed lineage kinase domain-like (MLKL), 
leading to ATP depletion, calpain activation, PAR polymer 
accumulation or cell membrane permeabilization, and release of 
damage-associated molecular patterns, respectively [reviewed in 
Ref. (119, 120)]. Both a type I IFN-dependent JAK/STAT-driven 
activation of PKR as well as signaling by the PRR DAI (DNA-
dependent activator of IRFs) initiates necroptosis via RIP1/RIP3 
activation, respectively (117, 121).
Importantly, the activation of proapoptotic and pro-necrop-
totic pathways in respiratory infection can result in a structural 
disruption of the airway and the alveolar epithelial barrier, which 
is a major hallmark of respiratory disease and its progression 
to the acute respiratory distress syndrome (122, 123). In virus-
induced lung injury, especially expression of TRAIL, which can 
initiate both apoptosis as well as necroptosis has been correlated 
with more severe outcomes.
TRAiL-induced Cellular Stress and Death 
Pathways
TRAIL and Its Receptors
As described earlier, TRAIL belongs to the superfamily of TNF 
ligands and has been reported to be inducible by both type I and 
type III IFNs. TRAIL has been found to be present in various 
cells of the immune system, among them natural killer (NK) cells, 
T cells, NK T cells, DC subsets such as IFN-γ-producing killer 
DCs and macrophages, and can be displayed in large amounts on 
the cell surface or be shed upon IFN- and/or pro-inflammatory 
cytokine signaling (124–126). In addition to cells of the immune 
system, fibroblasts have been shown to produce TRAIL after IFN-
γ treatment or viral challenge. Also, club cells and the alveolar 
epithelium have been reported to produce TRAIL (127–130). 
Similar to other ligands of the TNF superfamily, TRAIL is a 
homotrimeric type II transmembrane protein with a conserved 
C-terminal extracellular domain that mediates receptor binding 
and can be cleaved by metalloproteinases to generate a soluble 
mediator (131). However, TRAIL can induce cell death also in its 
membrane-bound form, that is, similar to TRAIL expression lev-
els and TRAIL shedding, upregulated by type I IFN (126). Direct 
cell-to-cell TRAIL–DR interactions have been demonstrated to 
play a role in macrophage, NK as well as CD4+ T cell-mediated 
induction of cellular death (132, 133).
In humans, five different binding partners for TRAIL are 
present: the membrane-bound DR4 (TRAIL-R1) and DR5 
(TRAIL-R2) that both induce a proapoptotic signaling cascade, 
the membrane-bound anti-apoptotic decoy receptors (DcR)1 
and DcR2, and the soluble interaction partner osteoprotegerin 
(134). In the murine system, only DR5 has been identified to 
ligate to TRAIL (135). In the human respiratory compartment, 
both DR4 and DR5 have been demonstrated to be present under 
steady-state conditions (136, 137). However, upon viral infection, 
cell-sensitivity to TRAIL-induced apoptosis is enhanced, which 
has been attributed to increased TRAIL receptor expression 
especially on infected cells, as DR levels are markedly increased in 
IAV-, adenovirus-, and paramyxovirus-infected cells in contrast 
to non-infected bystander cells (10, 138, 139). Of note, studies on 
the dependency of DR upregulation upon type I IFN signaling 
after IAV infection have yielded conflicting results in different 
strains of mice (10, 74), highlighting the complex interplay of 
IFN-induced cascades in a host- and tissue-specific context, 
whereas the exact virus- and host-specific mechanisms for DR 
regulation remain less well defined. Moreover, previous assump-
tions that also DcR expression would correlate with cell-sensitivity 
to TRAIL-induced cell death could not be experimentally verified 
(125).
TRAIL-Induced Signaling Cascades
Tumor necrosis factor-related apoptosis-inducing ligand ligation 
to the proapoptotic receptors DR4 or DR5 triggers a trimerization 
of the receptors. Subsequently, depending on additional stimuli, 
presence or absence of adaptor molecules or inhibitory proteins, 
different signaling pathways can be activated (Figure 2). In the 
classical TRAIL-dependent extrinsic apoptosis induction, the 
proteins RIP, TRADD, and FADD are subsequently recruited 
to the DR cytoplasmic domain upon TRAIL ligation (140, 141). 
These factors and the proapoptotic DRs all share a cytoplasmic 
death domain (DD), which is lacking or truncated and thus 
inactive in the DcR. The DD plays a central role in the concerted 
formation of the death-inducing signaling complex (DISC). DISC 
formation exposes a second functional domain of FADD, the 
death effector domain that is directly able to recruit pro-caspase-8 
FiGURe 2 | TRAiL/DR5-mediated cellular signaling pathways. In presence of RIP1, TRADD, and FADD, TRAIL ligation to DR5 results in apoptosis induction, 
which is initiated by recruitment of the pro-caspase-8 or -10 to FADD. These in turn activate the effector caspases-3 and -7, which leads to DNA fragmentation and 
apoptosis induction. In addition, TRADD can trigger a TRAF2- and JNK-dependent activation of Bax and subsequent release of mitochondrial cytochrome c, 
inducing the pro-caspase-9 activation. In the presence of CYLD, c-FLIP or absence of sufficient amounts of FADD or pro-caspase-8, TRAIL ligation to DR triggers 
the interaction of RIP1 and RIP3 kinase, which in turn cause cell death via induction of MLKL and/or PARP-1. In the presence of cIAPS, FADD is not recruited to 
DR5 upon TRAIL ligation, and TAK1 is activated by TRADD/TRAF2 interactions. TAK1 induces NEMO followed by IκB degradation and NFκB activation, as well as 
MKK and JNK activation leading to AP-1 nuclear translocation; both events promote the production of cytoprotective factors such as XIAP, cIAPs, and c-FLIP. 
Additionally, TAK1 triggers AMPK activation and thus mTORC inhibition, which results in enhanced autophagic activity. Abbreviations: AP-1, activator protein 1; TNF, 
tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand; DR5, death receptor 5; RIP1, receptor-interacting serine/threonine-protein kinase 1; TRADD, 
TNF receptor type 1-associated death protein; FADD, Fas-associated protein with death domain; TRAF, TNF receptor-associated protein; JNK, Janus kinase; Bax, 
Bcl-2-associated X protein; c-FLIP, cellular FADD-like IL-1β-converting enzyme-inhibitory proteins; RIP, receptor-interacting serine/threonine-protein; MLKL, mixed 
lineage kinase domain-like; PARP-1, poly-ADP-ribose (PAR) polymerase 1; cIAP, cytoprotective factors including inhibition of the autophagic machinery; XIAP, 
X-linked inhibitor of apoptosis protein; AMPK, AMP-activated protein kinase; mTORC, mammalian target of rapamycin complex; TRAF2, TNF receptor-associated 
protein 2; MKK, mitogen-activated protein kinase.
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and pro-caspase-10. How exactly DISC formation induces cas-
pase activation is still under debate. The most probable scenarios 
include either an autocatalytic cleavage of caspase-pro-domains 
enabled by the spatial proximity between pro-caspases (generated 
by their recruitment to DISC), by pro-caspase dimerization, or by 
pro-caspase conformational stabilization (125). Removal of the 
pro-domain of caspase-8 and caspase-10 results in the activation 
of the effector caspases-3 and -7, which cleave DNA fragmenta-
tion factor 45 and lead to apoptosis (142, 143). Moreover, TRAIL-
binding to DR4 and DR5 can induce the JNK either via caspase-8 
or recruitment of TNF receptor-associated protein 2 (TRAF2) to 
the DISC complex, which results in the activation of the intrinsic 
apoptotic cascade by Bax-dependent mitochondrial cytochrome 
c release (144). In addition, TRAIL signaling is also able to induce 
necroptosis by both activating the RIP1/RIP3 kinase downstream 
effectors PARP-1 and MLKL, contributing to epithelial cell death 
and tissue injury (145–147).
It has become apparent in recent years that TRAIL signaling 
is closely linked to induction of autophagy, a process generally 
associated with the blockade of apoptosis and necrosis. Indeed, 
autophagy has been reported to improve cellular survival in cell 
stress by catabolic removal of cytoplasmic long-lived proteins 
and damaged organelles. It also contributes to viral clearance 
and the transfer of viral material to endosomal-/lysosomal-
located TLR7 or MHC class II compartments for the activation 
of adaptive immunity (148). Several studies outline that TRAIL 
ligation to DR5 can result in a TRAF2-dependent activation 
of TAK1 (MAP3K7) that has been attributed a central role in 
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TRAIL-induced autophagy activation (149). TAK1 modulates the 
IKK-dependent translocation of NFκB, and it also induces JNK 
activation via mitogen-activated protein kinase. Both events lead 
to expression of autophagy-related factors including inhibition of 
the autophagic machinery (cIAP)1, cIAP2, X-linked inhibitor of 
apoptosis protein, and c-FLIP (150, 151). Especially, c-FLIP has 
been associated with desensitization of cells to TRAIL-induced 
apoptosis, favoring autophagy-related cascades (152). Another 
study revealed that upon TRAIL signaling the AMP-activated 
protein kinase (AMPK) is activated. AMPK in turn inhibits the 
mammalian target of rapamycin complex 1 that itself is an inhibi-
tor of autophagy, thus the activation of the autophagic machinery 
is promoted (153). The decision if TRAIL signaling results 
rather in necroptotic or apoptotic cell death or in activation of 
autophagy seems to be dependent on the presence of cIAPs that 
promote RIP kinase ubiquitination and degradation (146), but 
also on the balance between active caspases and autophagic pro-
teins such as Beclin-1 (154, 155). This suggests a scenario where 
autophagy is activated as cell protective mechanism until cell 
stress—as executed by enhanced TRAIL signaling or additional 
viral infection—increases over a threshold to favor cell death 
induction. Accordingly, as TRAIL signaling is not restricted to 
infected cells, excessive cell death activation might be limited by 
autophagy induction in non-infected bystander cells. However, 
autophagy is not only related to cell survival but can also posi-
tively affect apoptosis and induce—even if the exact mechanisms 
are still under debate—autosis, the autophagy-related cell death, 
another mode of TRAIL to trigger cell death (156, 157). Of note, 
autophagy activation needs to be placed into its virus-specific 
context, as some viruses, including Dengue virus, poliovirus, and 
Coxsackie B virus (158), can exploit autophagic pathways for their 
own replication and thus promote apoptosis and tissue injury.
TRAiL in Acute Respiratory viral infection
As discussed above, TRAIL is a potent activator of cell death. 
However, its signaling outcomes can differ largely depending on 
its delivered form (e.g., membrane-bound versus soluble), the 
availability of DRs on the target cell membrane, alternate intracel-
lular pathways that might be activated and finally the pathogen 
itself, as it might exploit TRAIL-induced pathways for its own 
survival and replication. In acute respiratory infection, TRAIL 
signaling is often part of an IFN-driven overshooting inflam-
matory reaction that promotes unspecific tissue injury and thus 
disease severity by increasing functional and structural changes 
in infected but also non-infected cells, as will be outlined below.
Influenza A Virus
The release and effects of TRAIL have been especially well studied 
in IAV infection in the last decade. Earlier studies reported that 
within 3 days after infection, bronchial, bronchiolar, and alveolar 
epithelial cells undergo apoptosis (159). This early induction of 
cell death is mainly attributed to direct apoptosis induction by the 
virus itself, as IAV actively promotes apoptosis for efficient viral 
replication (160). Herein, the viral NS1 and PB-F2 proteins not 
only play a crucial role (161, 162) but also the viral M2 protein 
has been implicated in this process as it inhibits autophagy in 
infected cells (163). In addition, our own data revealed that 
later in IAV in vivo infection, the recruitment of bone marrow-
derived macrophages via the CC chemokine receptor type 2 
(CCR2)–CC-chemokine ligand 2 (CCL2) axis significantly 
contributes to alveolar cell apoptosis and structural damage of 
the alveolar epithelium (5). Studies by Wurzer et  al. (164) had 
previously demonstrated that IAV promotes the production of 
proapoptotic factors in an auto- and paracrine fashion via NFκB 
transcriptional activation by IAV (164). Subsequently, Brincks 
et  al. (6) elucidated that human peripheral blood mononu-
clear cell treated with IAV released TRAIL and that increased 
TRAIL levels correlated with type I as well as II IFN induction. 
Additionally, TRAIL sensitivity was increased in influenza virus-
infected cells. In line, our investigations could elucidate that IAV 
triggers a PKR-dependent translocation of NFκB that results the 
production of type I IFNs. These in turn induce, via ligation to the 
IFNAR receptor complex, expression and shedding of TRAIL by 
bone marrow-derived macrophages (10). In addition, Davidson 
et  al. (74) demonstrated that type I IFN application to IAV-
infected mice increased morbidity and lung injury, which could 
be attributed to both DR5 and TRAIL upregulation inducing 
epithelial cell apoptosis. Importantly, Högner et al. also reported 
that the IAV strain used in these studies, A/PR8 (H1N1), which 
is highly pathogenic for mice, induced an approximately 800-fold 
induction in macrophage TRAIL expression, whereas the lower 
pathogenic virus A/X-31 (H3N2) only stimulated TRAIL by a 
factor of eight. Of note, the relation between TRAIL induction 
and IAV strain-specific pathogenicity also translates to the highly 
pathogenic avian H5N1 IAV, causing severe pneumonia in mice 
as well as in humans (165, 166). Moreover, human infection 
with both the highly pathogenic H5N1 as well as the pandemic 
1918 H1N1 IAV strains are characterized by a massive influx of 
mononuclear phagocytes into the alveoli, which is correlated with 
extensive alveolar epithelial cell apoptosis (97, 167). Additionally, 
macrophages gained from bronchoalveolar lavages of patients 
presenting with ARDS caused by the pandemic H1N1/2009 virus 
strain showed high surface expression and release of TRAIL (10). 
Another recent report demonstrates that in highly pathogenic 
avian influenza, in addition to macrophages also the alveolar 
epithelium might be involved in causing elevated levels of TRAIL 
in the alveolar space (130). Besides its role in apoptosis, TRAIL 
signaling upon IAV infection has also been implicated in the 
induction of necroptosis in fibroblasts, DCs, and lung epithelial 
cells (146, 147, 168). Rodrigue-Gervais et al. (146) demonstrated 
that lack of cIPA2 promotes RIP3 kinase-mediated necroptosis 
in response to TRAIL—but also the proapoptotic factor FasL—
released from hematopoietic cells. This contributed to severe lung 
epithelial degeneration and increased mortality, even though 
viral control was not compromised. Nogusa et al. (147) further 
elucidated that IAV-induced necroptosis depends on RIP3 kinase 
activation of MLKL, and that RIP3 kinase deficiency, similar to 
cIAP2-deficiency, increased IAV-susceptibility in vivo.
In IAV infection, as mentioned earlier, DR5 expression is 
elevated on infected alveolar epithelial cells, but not in non-
infected cells in  vivo, which might impact on TRAIL suscep-
tibility to apoptosis induction (10). However, both infected as 
well as neighboring bystander cells were found to be targeted 
for apoptosis induction by macrophage-released TRAIL. 
10
Peteranderl and Herold The IFN/TRAIL Signaling Axis
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 313
Nonetheless, we could recently show that specifically in non-
infected cells within the IAV-infected lung, TRAIL severely 
compromises the function of the ion channel Na,K-ATPase, 
which was mediated via induction of the stress kinase AMPK 
(11), thereby potentially revealing a cross-link to TRAIL-
induced autophagic cell stress pathways in bystander cells both 
in vitro and in vivo. The TRAIL-induced and AMPK-mediated 
downregulation of the Na,K-ATPase, a major driver of vertical 
ion and fluid transport from the alveolar airspace toward the 
interstitium, resulted in a reduced capacity of IAV-infected mice 
to clear excessive fluid from the alveoli. Thus, TRAIL signaling 
contributes to intensive edema formation, a hallmark of disease 
in virus-induced ARDS (123). Notably, this effect of TRAIL on 
Na,K-ATPase expression was induced independently of cell 
death pathways elicited by caspases, as treatment of cells and 
mice with a specific caspase-3 inhibitor diminished apoptosis 
in alveolar epithelial cells but still allowed for the reduction of 
the Na,K-ATPase (11). Conclusively, treatment of IAV-infected 
mice with neutralizing antibodies directed against TRAIL or 
the abrogation of recruitment of TRAIL+ bone marrow-derived 
macrophages inhibited apoptosis of both non-infected and 
bystander cells. Thus, lung leakage due to loss of alveolar barrier 
function was reduced, whereas alveolar fluid clearance capacity 
was enhanced, resulting in reduced edema, improved survival, 
and outcome upon IAV challenge in vivo. However, TRAIL has 
also been shown to be upregulated on NK, DC, and on CD4+ and 
CD8+ T cells after IAV infection (169). Studies by Brincks et al. 
demonstrated that especially CD8+ T involved in cytotoxic T cell 
responses toward IAV and drive IAV-infected cells into apoptosis 
via TRAIL, thus contributing to efficient virus clearance (6, 170). 
In addition, both FasL and TRAIL are involved in DC-mediated 
CTL activation and cytotoxicity against IAV-infected cells 
(6, 171). Furthermore, studies showed delayed viral clearance 
upon neutralizing anti-TRAIL antibody administration (169, 
172). Our data, however, demonstrate that the transfer of 
TRAIL-deficient bone marrow into irradiated wild-type mice, 
resulting in loss of TRAIL production by bone marrow-derived 
macrophages upon IAV infection, does not impact on the capacity 
to fully clear viral particles from the lung at day 7 after infection, 
suggesting that other compensatory mechanisms are recruited to 
guarantee viral clearance (10). Taken together, in IAV infection, 
TRAIL acts both as an important mediator of infected cell kill-
ing but particularly as a detrimental factor contributing to tissue 
injury and impaired inflammation resolution when released in 
excessive amounts by recruited immune cells.
Respiratory Syncytial Virus
Respiratory syncytial virus is an important cause of respiratory 
tract infections especially in children worldwide. Generally, 
there seem to be virus-elicited anti-apoptotic mechanisms active 
in the lung epithelium, as RSV-infected primary human airway 
cells show a minimal cytopathic effect (173). However, several 
cell lines including small airway cells, primary tracheal-bronchial 
cells, and A549 and HEp-2 showed increased expression of 
TRAIL and its ligands DR4 and DR5 in an in vitro RSV infection 
model (174). Moreover, soluble TRAIL released from leukocytes 
was elevated in the bronchoalveolar lavage fluid of patients with 
RSV-associated respiratory failure, suggesting that similar to IAV, 
TRAIL contributes to RSV-induced epithelial injury and disease 
progression (137).
Coronaviruses
Also in CoV respiratory tract infection, TRAIL levels, but less so 
FasL, have been reported to be markedly elevated (175, 176). For 
SARS-CoV that presents with a severe damage to both the upper 
and lower respiratory tract (177), especially DCs respond with a 
strong induction of TRAIL production, which was suggested to 
correlate to increased cellular lung infiltrations present in SARS-
CoV patients (175). Interestingly, SARS-CoV infection drives 
cells into apoptosis by a PKR-driven but eIF2α-independent 
pathway (178), which might—similarly as seen in IAV infec-
tion—suggest a PKR-induced and autocrine/paracrine executed 
activation of apoptosis.
Also MERS-CoV, which causes pneumonia and respiratory 
failure, has been demonstrated to induce profound cell death 
within 24 h of infection, irrespective of viral titers produced by 
the infected cells. However, type I IFN expression is strongly 
reduced in MERS-CoV in comparison to seasonal human CoV 
in in vitro infection models, including human monocyte-derived 
macrophages, Calu-3, and human lung fibroblasts (179, 180), 
which might also dampen downstream TRAIL induction. 
Therefore, the exact mechanism by which MERS-CoV promotes 
cell death remains to be investigated.
THe iFN/TRAiL AXiS iN BACTeRiAL 
SUPeRiNFeCTiON AFTeR viRAL iNJURY
Recurrently, viral infections of the respiratory tract are fol-
lowed by outgrowth of colonizing Gram-positive bacteria that 
aggravates the course of illness. This is well documented for 
IAV, where “super” infections with Streptococcus pneumoniae 
and Staphylococcus aureus are the most frequent and increase 
viral pneumonia-associated morbidity and mortality (181). 
During the 1918 IAV pandemic, bacterial pneumonia was 
evident in most cases (182) and also during the recent 2009 
H1N1 pandemic, coinfections were a relevant factor for severe 
disease in a young patient population without comorbidities 
(183). Interestingly, virus-induced elevation of the type I IFN 
response levels might promote secondary bacterial outgrowth 
by several mechanisms [reviewed in Ref. (184)]. In line, it has 
been repeatedly demonstrated that lack of type I IFN signaling 
results in better bacterial clearance and increased survival rates in 
IAV- and S. pneumoniae-superinfected mice (185–187). Herein, 
IFN-induced apoptosis induction as well as depletion or impaired 
recruitment of lymphocyte subsets necessary for bacterial control 
play a critical role (188, 189). Bacterial clearance from the lung has 
been reported to rely on sufficient phagocyte generation, recruit-
ment, and survival. Type I IFN has been demonstrated to cause 
apoptosis in bone marrow-derived granulocytes, affecting the 
numbers of recruited neutrophils (189), but also to impair expres-
sion of the cytokines CXCL1 (or KC) and CXCL2 (or MIP-2), 
thus inhibiting neutrophil recruitment to the lungs with severe 
effects on survival of superinfected mice (185). A recent report 
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by Schliehe et al. (190) elucidated the mechanistic background for 
impaired CXCL1 expression and secretion and demonstrated that 
type I IFNs activate the histone methyltransferase Setdb2, which 
in turn represses the Cxcl1 promoter and thus impairs neutrophil 
recruitment and bacterial clearance. Moreover, type I IFN pro-
duction decreases CCL2 production, thus inhibiting macrophage 
recruitment, which as well has been reported to have detrimental 
effects on bacterial clearance and disease progression in bacterial 
superinfection after viral insult in vivo (186). In addition, type I 
IFNs also impair γδ T cell function and IL-17 release, which was 
shown to increase susceptibility to S. pneumoniae superinfection 
after IAV challenge (187). Also in S. aureus pneumonia, a robust 
type I IFN response is correlated to excessive morbidity and 
tissue injury (191). In a model of polyI:C, S. aureus (methicillin-
resistant strain, MRSA) superinfection, polyI:C treatment prior 
to bacterial infection enhanced type I IFN levels and decreased 
bacterial clearance and survival (192). Furthermore, Shepardson 
et al. (193) demonstrated that late type I IFN induction rendered 
mice more susceptible to secondary bacterial pneumonia in a 
model of IAV–MRSA superinfection.
Only limited data are available on a direct role of TRAIL in 
respiratory disease progression due to bacterial superinfections. 
In a model of IAV–Haemophilus influenza infection, neither 
deficiency for CC chemokine receptor type 2, inhibiting bone 
marrow-derived macrophage recruitment, nor deficiency of Fas 
or TNFR1 impacted outcome (194). Yet, during S. pneumoniae 
single infection, early cell death of macrophages is thought to limit 
an exuberant inflammatory reaction and accordingly, a study by 
Steinwede et  al. (195) revealed that neutrophil-derived TRAIL 
limits tissue injury by inducing cell death in DR5-epressing lung 
macrophages in bacterial mono-infection (195). In contrast, 
in the IAV–S. pneumoniae superinfection mouse model, IAV-
induced TRAIL has a detrimental effect on overall mortality 
(7), as TRAIL-induced epithelial injury enhanced bacterial 
outgrowth of S. pneumoniae—administered at day 5 after IAV 
infection—markedly. Importantly, administration of anti-TRAIL 
neutralizing antibodies enhanced bacterial control by the host 
organism. Thus, the activation of IFN/TRAIL-mediated signal-
ing in viral infection has detrimental implication for outcome 
of secondary bacterial infection following viral insult, rendering 
the IFN/TRAIL signaling axis an interesting therapeutic target 
not only in respiratory viral infections but also in complicating 
bacterial superinfection.
iFN/TRAiL AXiS iN CHRONiC LUNG 
DiSeASeS
An increasing number of reports connect progression of chronic 
respiratory disease to acute respiratory virus infection or proap-
optotic signaling events. In fact, TRAIL has been reported to be 
a critical determinant for promoting the development of chronic 
lung disease in early life (196); targeting TRAIL by genetic dele-
tion or neutralizing antibody application in early-life respira-
tory infections ameliorated infection-induced histopathology, 
inflammation, as well as emphysema-like alveolar enlargement 
and lung function. Furthermore, TRAIL was also shown to play 
a role in the development of allergy and asthma. TRAIL is not 
only elevated in the sputum of asthmatic patients but has also 
been reported to be highly expressed in an experimental mouse 
model of asthma, where it induces CCL20 secretion by bronchial 
epithelial cells, thus promoting TH2 cell responses and airway 
hyperreactivity (197).
In COPD, acute exacerbations driven by viral and bacterial 
infection are a major factor increasing both mortality and mor-
bidity, and both influenza and S. pneumoniae have been identified 
among the most common causes of COPD exacerbations (198). 
Indeed, primary bronchial epithelial cells isolated from subjects 
with COPD show an impaired production of type I IFN (199), 
which has been implied in the enhanced susceptibility of COPD 
patients to respiratory infections; however, even in absence of 
high IFN induction, both an abnormally elevated loss of alveolar 
epithelial cells due to apoptosis as well as elevated TRAIL and 
DR5 levels were reported (200), implying a possible link between 
viral/bacterial induction of TRAIL and acute exacerbations in 
COPD. TRAIL induction has also been directly linked to ciga-
rette-smoke exposure, a common cause of COPD, and TRAIL 
deficiency resulted in decreased pulmonary inflammation and 
emphysema-like alveolar enlargement in  vivo (201). Moreover, 
increased levels of both TRAIL and DR5 were associated to 
impaired lung function and increased systemic inflammation 
in human COPD patients (202). While alveolar epithelial cell 
death is closely connected to idiopathic pulmonary fibrosis (IPF), 
TRAIL and its receptors DR4 and DR5 in AEC were shown to 
be upregulated in IPF lungs (129). Also, in pulmonary arterial 
hypertension virus infection is considered to be a possible risk 
factor (203), and pulmonary hypertension has been reported to 
be a side effect of prolonged treatment with type I IFN (204, 205). 
In line, TRAIL has been closely linked to disease progression in 
pulmonary hypertension. TRAIL has been found to be increased 
within pulmonary vascular lesions of patients with pulmonary 
hypertension (206) and also in a mouse model of hypoxia-induced 
pulmonary hypertension, levels of soluble TRAIL correlated with 
right ventricular systolic pressure, right ventricular hypertrophy, 
and pathologic alterations (33, 34). Importantly, neutralizing 
antibody-treatment against TRAIL showed positive effects on 
survival while reducing pulmonary vascular remodeling (207). 
Notably, the extent to which infection-induced TRAIL release 
causes or exacerbates chronic lung disease or in how far TRAIL 
production in chronic lung diseases affects susceptibility to 
respiratory viral and complicating bacterial infection remains to 
be elucidated.
OUTLOOK: THeRAPeUTiC CONCePTS 
TARGeTiNG TRAiL iN ACUTe 
ReSPiRATORY viRAL iNFeCTiON
Respiratory viral infections are major causative agents for lung 
injury and ARDS; however, in many cases antivirals are not suf-
ficient to limit disease (208). Besides the fact that most viruses are 
subject to strong selective pressures that favor quickly evolving, 
drug-resistant virus variants, recent advances in understanding 
the processes that contribute to tissue injury and ARDS highlight 
12
Peteranderl and Herold The IFN/TRAIL Signaling Axis
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 313
a crucial role of immune-related, IFN-driven events. Therefore, 
novel therapeutic strategies often aim to improve the outcome of 
severe respiratory infection by modulating host cell responses; 
however, to date, clinical trials trying to improve severe viral 
infections or ARDS outcomes by targeting host pathways have 
not resulted in approval of new drugs (122).
Of note, for establishment of such therapies it has to be 
considered that the timing and intensity of induction and 
amplification as well as of dampening and termination of the 
IFN-driven immune response needs to precisely match the 
pathogen- and organ-specific requirements of a given infection. 
A non-controlled regulation of these processes may lead to either 
an unrestricted pathogen spreading or, on the other extreme, to 
an overshooting inflammatory response, including the increased 
production of pro-inflammatory and proapoptotic mediators, 
elevated levels of recruited immune cells, and/or aberrant 
repair processes. Notably, both too low and too high levels of 
IFN-induced effects facilitate disease progression with a possible 
increase of fatal outcomes in ARDS patients (78). Accordingly, 
preclinical in  vivo studies of IFN-directed therapies yielded 
seemingly adverse results, depending on the context, timing, 
and dosage of IFN modulation. However, in multiple settings 
of acute respiratory viral infection, studies demonstrate that 
an exaggerated signaling derived from type I IFN in an already 
inflamed tissue contributes to worsened outcomes, and impor-
tantly, might favor secondary bacterial superinfection [e.g., Ref. 
(75, 76, 209)]. Interestingly, Davidson et al. (209) demonstrated 
that type III IFN release upon influenza challenge—in contrast 
to type I IFN induction—does not trigger an unbalanced inflam-
matory response that critically contributes to respiratory disease 
progression in  vivo, highlighting it as a possible therapeutic 
option in IAV-induced lung injury. Most likely, this effect derives 
from the lack of the IFN-λR1/IL-10R2 receptor complex, but 
presence of IFNAR, on immune cells, including bone marrow-
derived macrophages. Nonetheless, other reports identify IFN-λ 
as a driver of macrophage polarization to an inflammatory M1 
phenotype (41) that has been attributed to further promote an 
overshooting inflammatory response, highlighting the need for 
further studies of type III IFN biology in pathogen-associated 
disease progression.
As generally IFN-directed therapeutic approaches target 
various downstream signaling events that might both act 
beneficially as well as detrimentally on viral replication and 
pathogenesis, a further approach is to address specific ISGs 
that primarily show detrimental effects on disease progression. 
As outlined above, TRAIL or its downstream signaling events 
might comprise a suitable target for adjunct therapies in addi-
tion to antivirals. Accordingly, our own data in a preclinical 
mouse model of IAV infection demonstrate a clear benefit of 
the systemic application of neutralizing antibodies against 
TRAIL at days 3 and 5 postinfection for lung injury, morbidity, 
and mortality (10, 11). Targeting TRAIL as a major determinant 
of disease severity in respiratory viral infections including IAV, 
but also RSV and CoV, may yield therapeutic approaches that 
are superior to IFN-directed strategies, as they seemingly do 
not bear the risk of compromising host defense. Yet, it should 
be thoroughly excluded that blocking TRAIL-induced cell 
death of infected cells will not lead to an overwhelming viral 
spreading, especially as reports on viral loads upon TRAIL 
inhibition in preclinical models of IAV are controversial (6, 10, 
170). Accordingly, additional studies are needed to understand 
how and to which extent virus-infected cells can be killed or 
viral spreading can be controlled by other means in the absence 
of TRAIL. Moreover, targeting pathways and signaling hubs 
downstream of TRAIL/DRs, such as AMPK (11), in a well-timed 
and lung compartment-specific way, may open new therapeutic 
avenues but requires more detailed preclinical studies on effica-
cies and side effects. A valid approach might be the use of a 
combination therapy of such a treatment together with a clas-
sical antiviral drug therapy limiting viral replication; however, 
exact dosage, timing, kinetics, and application routes remain to 
be defined.
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